See Also: U.S. Guidelines for HIV Testing, Prevention, and Treatment; Starting HIV Treatment; Comparing HIV Drug Regimens; Salvage Treatment for HIV; Innovative Approaches to HIV Treatment
Selected Recent Articles
- Ask A Pharmacist: With a new tenofovir, should you switch to Descovy, Genvoya or Odefsey? (September 2016, Beta Blog)
- Kidney and Bone Markers Improve in Patients With Renal Impairment After Switch from TDF to TAF. (August 2016, TheBodyPro)
- Studies examine switch to TAF-based regimens in patients with renal impairment. (July 2016, Healio)
- Switch From TDF to TAF Tied to Better Bone Mineral Density and Bone Markers. (July 2016, TheBodyPro)
- Integrase Inhibitors Work Well to Treat NNRTI Drug Resistant HIV. (July 2016, Beta Blog)
- Nearly Two-Thirds Modify First-Line HIV Treatment Regimen in Large Study. (April 2016, The BodyPro)
- Less Switching From Newer HIV Drug Combinations, and Better HIV Control. (March 2016, HIV Treatment Alerts)
- Switching to Emtricitabine/Tenofovir Alafenamide (F/TAF) Maintains Viral Suppression with Better Bone and Kidney Safety. (February 2016, TheBodyPro)
- People taking a large number of non-HIV-related medications more likely to stop or change HIV drugs. (January 2016, AIDSmap)
- Switching to Abacavir/Dolutegravir/Lamivudine (Triumeq) Maintains Undetectable Viral Load. (October 2015, TheBodyPro)
- HIV-positive patients in Africa do well on three second-line ART regimens. (July 2015, AIDSmap)
- Second-line ART patients reach viral re-suppression following intensified adherence support. (July 2015, AIDSmap)
- High treatment failure rate among Thai children switching to second-line ART. (April 2015, AIDSmap)
- Pill A, Pill B: simplified second-line treatment for low-income countries. (August 2014, HIV i-Base)
- Time to first-line failure in the IeDEA cohort. (August 2014, HIV i-Base)
- Switching from first-line ART with suppressed viral load linked to treatment failure. (July 2014, AIDSmap)
- Dolutegravir demonstrates good efficacy despite resistance. (July 2014, AIDSmap)
- DTG-Based Regimens Are Active in INI-Naive Patients With a History of NRTI Resistance. (July 2014, NATAP)
- Effect of viral suppression below 20 copies of HIV-RNA /mL of plasma on virological outcome of treated HIV- infected patients. (July 2014, NATAP)
- Failure Risk Similar With 20 to 50 Copies and Always Under 20 Copies. (July 2014, NATAP)
- Good Response and Resistance Record in Naive and Experienced Starting Dolutegravir. (July 2014, NATAP)
- Many People With HIV Could Switch to Newer, Safer Regimens. (July 2014, Poz)
- Changing Meds May Be Unneeded After PI Treatment Failure. (June 2014, Poz)
- People starting therapy on a boosted protease inhihibitor don’t need to switch after one virological failure episode, study indicates. (June 2014, AIDSmap)
- FDA OKs Switching From Stable HIV Regimen to Complera. (December 2013, Poz)
- Lipids Respond Well to Switch From Boosted PI to Rilpivirine/Tenofovir/Emtricitabine (Complera), Study Finds. (October 2013, TheBodyPro)
- Costs Spike for 2nd- and 3rd-Line ARVs and Late Treatment. (September 2013, Poz)
- Study supports WHO recommendations for second-line HIV therapy in resource-limited countries. (July 2013, AIDSmap)
- Virologic Failure in 40% of Perinatally Infected US Children – Regimen Switching Slow. (March 2013, NATAP)
- Can people with resistant HIV omit NRTIs when switching from a failing regimen? (March 2013, AIDSmap)
